Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"image","alt":"Creative Medical Technology Holdings, Inc.","displaySize":"","headline":null,"caption":"Creative Medical Technology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GXuNPn9qVk4jpjMkZ_nOOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe","width":300,"height":43}},"lazy":false},{"type":"text","content":"Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study","length":94,"tagName":"p"},{"type":"text","content":"PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded dose escalation for its ongoing Phase 1/2 trial of StemSpine® using AlloStem™ (CELZ-201-DDT), the Company’s proprietary allogeneic (donor) cell therapy for chronic lower back pain caused by degenerative disc disease (DDD). This regulatory milestone follows compelling interim blinded data demonstrating statistically significant pain reduction and improved mobility among trial participants.","length":677,"tagName":"p"},{"type":"text","content":"The first-of-its-kind study employs a minimally invasive ultrasound-guided injection of CELZ-201-DDT in an outpatient setting, with a 4:1 treatment-to-placebo ratio. With half of the trial now completed, the study has reported no dose-limiting toxicities or serious adverse events, reinforcing both the safety and potential efficacy of the therapy. The FDA’s authorization allows the Company to expand dosing, further optimizing therapeutic outcomes. The Data Safety Monitoring Board (DSMB) and the Institutional Review Board (IRB) have already approved the new dosing strategy and it has been implemented.","length":606,"tagName":"p"},{"type":"text","content":"Key Trial Milestones:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strong Safety Profile: No serious adverse events reported in the first half of the study.","length":89,"tagName":"p"}]},{"val":[{"type":"text","...

More updates from Creative Medical Technology Holdings, Inc.